ReviewBlood2018
Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia
Review in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 32 citations in OpenAlex.
- How multispecific molecules are transforming pharmacotherapy.Nature reviews. Drug discovery · 2025Review
- Designing better gene therapies for lysosomal storage disorders using engineered enzymes.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Exploration of biomarkers for inhibitor development in persons with hemophilia A.Research and practice in thrombosis and haemostasis · 2025Article
- Article
- Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS).Research and practice in thrombosis and haemostasis · 2024Article
- Factor IX administration in the skin primes inhibitor formation and sensitizes hemophilia B mice to systemic factor IX administration.Research and practice in thrombosis and haemostasis · 2023Article
- Antigen-dependent modulation of immune responses to antigen-Fc fusion proteins by Fc-effector functions.Frontiers in immunology · 2023Article
- Sequential Use of Efgartigimod and Romiplostim Restored Platelet Response in Two Multi-Refractory Thrombocytopenic Patients, Previously Treated with Thrombopoietin Receptor Agonists.Mediterranean journal of hematology and infectious diseases · 2023Article
- Recombinant factor VIII Fc for the treatment of haemophilia A.European journal of haematology · 2021Review
- Selective Depletion of Antigen-Specific Antibodies for the Treatment of Demyelinating Disease.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- Induction of Tolerance to Therapeutic Proteins With Antigen-Processing Independent T Cell Epitopes: Controlling Immune Responses to Biologics.Frontiers in immunology · 2021Review
- Immunogenic properties of immunoglobulin superfamily members within complex biological networks.Cellular immunology · 2020Review
- Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy.Haemophilia : the official journal of the World Federation of Hemophilia · 2020Review
- Factor VIII Fc Fusion Protein but not FVIII Drives Human Monocyte-Derived Dendritic Cell Activation via FcγRIIa.HemaSphere · 2020Article
- Tolerating Factor VIII: Recent Progress.Frontiers in immunology · 2019Review
- Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies.Frontiers in immunology · 2019Review
- The Neonatal Fc Receptor (FcRn): A Misnomer?Frontiers in immunology · 2019Review
- Immunomodulation in Primary Immune Thrombocytopenia: A Possible Role of the Fc Fragment of Romiplostim?Frontiers in immunology · 2019Review
- Recombinant factor VIII Fc fusion protein drives regulatory macrophage polarization.Blood advances · 2018Article
- Tolerance induction in hemophilia: innovation and accomplishments.Current opinion in hematology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Hemophilia, or inherited genetic deficiencies in coagulation factors, results in uncontrolled bleeding requiring replacement therapy with recombinant proteins given preventively or on demand. However, a major problem with these approaches is the potential for development of immune responses to the administered proteins due to the underlying genetic deficiency of the factor(s) throughout life. As such, there is great interest in developing strategies that avoid immunogenicity and induce immune tolerance. Recently, recombinant factor VIII (rFVIII) and rFIX fused to the crystallizable fragment (Fc) domain of immunoglobulin G (IgG) have been developed as therapeutic agents for hemophilia A and B, respectively. Although it is well known that the possession of an Fc domain confers IgG's longer-lasting circulating half-life, it is not generally appreciated that the Fc domain also confers immunoregulatory properties that are associated with the induction of tolerance. Here, we review some of the latest advances in our understanding of the tolerogenic abilities of IgG Fc and the impact of Fc-fusion proteins of rFVIII on the treatment of hemophilia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.